Devices for intradermal vaccination

Vaccine

Volumn 30, Issue 3, 2012, Pages 523-538

  Kis, Elsa E ^a   Winter, Gerhard ^a   Myschik, Julia ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Ballistic injection; Intradermal vaccination; Liquid jet injection; Microinjection; Microneedle

Indexed keywords

AMYLOPECTIN; ANTHRAX VACCINE; CARBOXYMETHYLCELLULOSE; CHITOSAN DERIVATIVE; CPG OLIGODEOXYNUCLEOTIDE; DIPHTHERIA TOXOID; DNA VACCINE; GOLD; HELIUM; HEMAGGLUTINATION INHIBITING ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN G; INFLUENZA VACCINE; LIPOPOLYSACCHARIDE; MALTOSE; N TRIMETHYL CHITOSAN; POLIOMYELITIS VACCINE; POLYGLACTIN; POLYGLYCOLIC ACID; POLYSTYRENE; QUIL A; RABIES VACCINE; RECOMBINANT ENVELOPE PROTEIN GP20; RECOMBINANT VACCINE; SILICON; STAINLESS STEEL; SWINE INFLUENZA VACCINE; TITANIUM; UNCLASSIFIED DRUG; VACCINE;

ANTHRAX; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTOURED SHOCK TUBE DEVICE; CONVERGENT DIVERGENT SUPERSONIC NOZZLE DEVICE; DERMIS; DIPHTHERIA; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; DRUG STABILITY; EPIDERMAL POWDER IMMUNIZATION; EPIDERMIS; GENE GUN; GENE GUN IMMUNIZATION; HEMATOMA; HEPATITIS B; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; INJECTION SITE BLEEDING; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; JET INJECTOR; LANGERHANS CELL; MANTOUX TECHNIQUE; MEAN RESIDENCE TIME; MEDICAL INSTRUMENTATION; MICROINJECTION; NEEDLE; NONHUMAN; PARTICLE MEDIATED EPIDERMAL DELIVERY; PARTICLE SIZE; POLIOMYELITIS; POWDER; PRIORITY JOURNAL; PROCEDURES; RABIES; REVIEW; SEASONAL INFLUENZA; SKIN REDNESS; SKINFOLD THICKNESS; SWINE INFLUENZA; SYRINGE; VACCINATION; VACCINE PRODUCTION; VELOCITY; VENTURI DEVICE;

DRUG DELIVERY SYSTEMS; EQUIPMENT AND SUPPLIES; HUMANS; INJECTIONS, INTRADERMAL; VACCINATION; VACCINES;

EID: 84355161907     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.020     Document Type: Review

References (210)

1. Payette P.J., Davis H.L. History of vaccines and positioning of current trends. Curr Drug Targets-Infect Disord 2001, 1(3):241.
2. Jenner E. Two cases of small-pox infection communicated to the foetus in utero under peculiar circumstances, with additional remarks. Med Chir Trans 1809, 1:271-277.
3. Jenner E. An inquiry into the causes and effects of the variolae vaccinae: a disease discovered in some of the western counties of England, particularly Gloucestershire, and known by the name of the Cow Pox 1798, Sampson Low, London.
4. Levine M.M. Can needle-free administration of vaccines become the norm in global immunization?. Nat Med 2003, 9(1):99-103.
5. Dowdle W. The principles of disease elimination and eradication. Bull World Health Organ 1998, 76(Suppl. 2):23-25.
6. Heymann D.L., Aylward L.B. Perspective-Global health: eradicating polio. N Eng J Med 2004, 351:1275-1277.
7. Lambert P.H., Laurent P.E. Intradermal vaccine delivery: will new delivery systems transform vaccine administration?. Vaccine 2008, 26(26):3197-3208.
8. WHO. Saftey of injections: global facts and figures. World Health Organization: Geneva; 2004.
9. Mitragotri S. Immunization without needles. Nat Rev Immunol 2005, 5(12):905-916.
10. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392(6673):245-252.
11. Mishra D., Mishra P.K., Dubey V., Dabadghao S., Jain N.K. Evaluation of uptake and generation of immune response by murine dendritic cells pulsed with hepatitis B surface antigen-loaded elastic liposomes. Vaccine 2007, 25(39-40):6939-6944.
12. Warger T., Schild H., Rechtsteiner G. Initiation of adaptive immune responses by transcutaneous immunization. Immunol Lett 2007, 109(1):13-20.
13. Combadière B., Mahé B. Particle-based vaccines for transcutaneous vaccination. Comp Immunol Microbiol Infect Dis 2008, 31(2-3):293-315.
14. Toebak M.J., Gibbs S., Bruynzeel D.P., Scheper R.J., Rustemeyer T. Dendritic cells: biology of the skin. Contact Dermatitis 2009, 60(1):2-20.
15. Amorij J-P., Hinrichs W.L.J., Frijlink H.W., Wilschut J.C., Huckriede A. Needle-free influenza vaccination. Lancet Infect Dis 2010, 10(10):699-711.
16. Stoitzner P., Sparber F., Tripp C.H. Langerhans cells as targets for immunotherapy against skin cancer. Immunol Cell Biol 2010, 88(4):431-437.
17. Auewarakul P., Kositanont U., Sornsathapornkul P., Tothong P., Kanyok R., Thongcharoen P. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine 2007, 25(4):659-663.
18. Belshe R.B., Newman F.K., Cannon J., Duane C., Treanor J., Van Hoecke C., et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004, 351(22):2286-2294.
19. Belshe R.B., Newman F.K., Wilkins K., Graham I.L., Babusis E., Ewell M., et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 2007, 25(37-38):6755-6763.
20. Brown H., Kasel J.A., Freeman D.M., Moise L.D., Grose N.P., Couch R.B. the immunizing effect of influenza A/New Jersey/76 (Hsw1N1) virus vaccine administered intradermally and intramuscularly to adults. J Infect Dis 1977, 136(December (Suppl. 3)):S466-S471.
21. Bryan J.P., Sjogren M.H., Macarthy P., Cox E., Legters L.J., Perine P.L. Persistence of antibody to hepatitis B surface antigen after low-dose, intradermal hepatitis B immunization and response to a booster dose. Vaccine 1992, 10(1):33-38.
22. Carcaboso á., Hernández R., Igartua M., Rosas J., Patarroyo M., Pedraz J. Enhancing immunogenicity and reducing dose of microparticulated synthetic vaccines: single intradermal administration. Pharm Res 2004, 21(1):121-126.
23. Halperin W., Weiss W.I., Altman R., Diamond M.A., Black K.J., Iaci A.W., et al. A comparison of the intradermal and subcutaneous routes of influenza vaccination with A/New Jersey/76 (swine flu) and A/Victoria/75: report of a study and review of the literature. Am J Public Health 1979, 69(December (12)):1247-1251.
24. Herbert F.A., Larke R.P.B., Markstad E.L. Comparison of responses to influenza A/New Jersey/76-A/Victoria/75 virus vaccine administered intradermally or subcutaneously to adults with chronic respiratory disease. J Infect Dis 1979, 140(August (2)):234-238.
25. Kenney R.T., Frech S.A., Muenz L.R., Villar C.P., Glenn G.M. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004, 351(22):2295-2301.
26. Kurugöl Z., Erensoy S., Aksit S., Egemen A., Bilgiç A. Low-dose intradermal administration of recombinant hepatitis B vaccine in children: 5-year follow-up study. Vaccine 2001, 19(28-29):3936-3939.
27. Egemen A., Aksit S., Kurugöl Z., Erensoy S., Bilgiç A., Akilli M. Low-dose intradermal versus intramuscular administration of recombinant hepatitis B vaccine: a comparison of immunogenicity in infants and preschool children. Vaccine 1998, 16(16):1511-1515.
28. Pancharoen C., Mekmullica J., Thisyakorn U., Kasempimolporn S., Wilde H., Herzog C. Reduced-dose intradermal vaccination against hepatitis a with an aluminum-free vaccine is immunogenic and can lower costs. Clin Infect Dis 2005, 41(November (10)):1537-1540.
29. Playford E.G.M., Hogan P.G.P., Bansal A.S.D.M., Kareena Harrison B.N., Drummond D.M., Looke D.F.M.M., et al. Intradermal recombinant Hepatitis B vaccine for healthcare workers who fail to respond to intramuscular vaccine. Infect Control Hosp Epidemiol 2002, 23(2):87-90.
30. Propst T., Propst A., Lhotta K., Vogel W., Konig P. Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Am J Kid Dis 1998, 32(6):1041-1045.
31. Redfield R.R., Innis B.L., Scott R.M., Cannon H.G., Bancroft W.H. Clinical evaluation of low-dose intradermally administered Hepatitis B virus vaccine. JAMA 1985, 254(December (22)):3203-3206.
32. Warrell M.J., Suntharasamai P., Sinhaseni A., Phanfung R., Vincent-Falquet J.C., Bunnag D., et al. An economical regimen of human diploid cell strain anti-rabies vaccine for post-exposure prophylaxis. Lancet 1983, 322(8345):301-304.
33. Mitragotri S. Current status and future prospects of needle-free liquid jet injectors. Nat Rev Drug Discov 2006, 543-548.
34. PATH. Intradermal delivery of vaccines: a review of the literature and the potential for development for use in low- and middle-income countries. Seattle: Program for Appropriate Technology in Health (PATH); 2009.
35. Leroux-Roels I., Vets E., Freese R., Seiberling M., Weber F., Salamand C., et al. Seasonal influenza vaccine delivered by intradermal microinjection: a randomised controlled safety and immunogenicity trial in adults. Vaccine 2008, 26(51):6614-6619.
36. Holland D., Booy R., De Looze F., Eizenberg P., McDonald J., Karrasch J., et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008, 198(5):650-658.
37. Bernard K.W., Mallonee J., Wright J.C., Reid F.L., Makintubee S., Parker R.A., et al. Preexposure immunization with intradermal human diploid cell rabies vaccine. Risks and benefits of primary and booster vaccination. JAMA 1987, 257(8):1059-1063.
38. Chen W, Gluud C. Vaccines for preventing hepatitis B in health-care workers. Cochrane Database Syst Rev 2005 (4).
39. Sangaré L., Manhart L., Zehrung D., Wang C.C. Intradermal hepatitis B vaccination: a systematic review and meta-analysis. Vaccine 2009, 27(12):1777-1786.
40. Mohammed A.J., AlAwaidy S., Bawikar S., Kurup P.J., Elamir E., Shaban M.M.A., et al. Fractional doses of inactivated poliovirus vaccine in Oman. New England J. Med. 2010, 362(25):2351-2359.
41. Resik S., Tejeda A., Mas Lago P., Diaz M., Carmenates A., Sarmiento L., et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. Journal of Infectious Diseases 2010, 201(May (9)):1344-1352.
42. Hickling J.K., Jones K.R., Friede M., Zehrung D., Chen D., Kristensen D. Intradermal delivery of vaccines: potential benefits and current challenges. Bull World Health Organ 2011, 89:221-226.
43. Etchart N., Hennino A., Friede M., Dahel K., Dupouy M., Goujon-Henry C., et al. Safety and efficacy of transcutaneous vaccination using a patch with the live-attenuated measles vaccine in humans. Vaccine 2007, 25(39-40):6891-6899.
44. Kendall M. Engineering of needle-free physical methods to target epidermal cells for DNA vaccination. Vaccine 2006, 24(21):4651-4656.
45. WHO. WHO recommendations on rabies post-exposure treatment and the correct technique of intradermal immunization against rabies. WHO/EMS/ZOO/966.
46. Kim Y.-C., Jarrahian C., Zehrung D., Mitragotri S., Prausnitz M.R. Delivery systems for intradermal vaccination. Curr Top Microbiol Immunol 2012, (351):77-112.
47. Kersten G., Hirschberg H. Needle-free vaccine delivery. Expert Opin Drug Deliv 2007, 4(5):459-474.
48. Kersten G., Hirschberg H. Antigen delivery systems. Expert Rev Vaccines 2004, 3(4):453-462.
49. O'Hagan D.T., Rappuoli R. Novel approaches to vaccine delivery. Pharm Res 2004, 21(9):1519-1530.
50. Glenn G.M., Taylor D.N., Li X., Frankel S., Montemarano A., Alving C.R. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med 2000, 6(12):1403-1406.
51. Glenn G., Kenney R., Plotkin S.A. Mass vaccination solutions in the skin. Mass vaccination: global aspects-progress and obstacles 2006, Springer, Berlin Heidelberg, p. 247-68.
52. Zhang L., Nolan E., Kreitschitz S., Rabussay D.P. Enhanced delivery of naked DNA to the skin by non-invasive in vivo electroporation. Biochim Biophys Acta 2002, 1572(1):1-9.
53. Tezel A., Paliwal S., Shen Z., Mitragotri S. Low-frequency ultrasound as a transcutaneous immunization adjuvant. Vaccine 2005, 23(29):3800-3807.
54. Bramson J., Dayball K., Evelegh C., Wan Y.H., Page D., Smith A. Enabling topical immunization via microporation: a novel method for pain-free and needle-free delivery of adenovirus-based vaccines. Gene Ther 2003, 10(3):251-260.
55. Choi M.J., Zhai H., Löffler H., Dreher F., Maibach H.I. Effect of tape stripping on percutaneous penetration and topical vaccination. Exogenous Dermatol. 2003, 2(5):262-269.
56. Frerichs D.M., Ellingsworth L.R., Frech S.A., Flyer D.C., Villar C.P., Yu J., et al. Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch. Vaccine 2008, 26(22):2782-2787.
57. Peachman K.K., Rao M., Alving C.R. Immunization with DNA through the skin. Methods 2003, 31(3):232-242.
58. Dean H.J., Chen D. Epidermal powder immunization against influenza. Vaccine 2004, 23(5):681-686.
59. EMA. ANNEX I. Summary of product characteristics. Available at [accessed: 28 April 2011]. http://wwwemaeuropaeu/docs/de_DE/document_library/EPAR_-_Summary_for_the_public/human/000957/WC500033848pdf;%202003.
60. Choi M.J., Maibach H.I. Topical vaccination of dna antigens: topical delivery of dna antigens. Skin Pharmacol Appl Skin Physiol 2003, 16(5):271-282.
61. Mantoux C. L'intradermo-reaction a la tuberculine et son interpretation clinique. Presse Medicale 1910, 18(10-3).
62. Laurent P.E., Bonnet S., Alchas P., Regolini P., Mikszta J.A., Pettis R., et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 2007, 25(52):8833-8842.
63. Flynn P.M., Shenep J.L., Mao L., Crawford R., Williams B.F., Williams B.G. Influence of needle gauge in mantoux skin testing. Chest 1994, 106(5):1463-1465.
64. Roth A., Sodemann M., Jensen H., Poulsen A., Gustafson P., Gomes J., et al. Vaccination technique, PPD reaction and BCG scarring in a cohort of children born in Guinea-Bissau 2000-2002. Vaccine 2005, 23(30):3991-3998.
65. Bricks L.F. Percutaneous or intradermal BCG vaccine?. J Pediatr (Rio J) 2004, 80(2):93-98.
66. Rubin BA. Pronged vaccinating and testing needle. U.S. patent 3194237; July 1965.
67. Kravitz H. A simplified technique for vaccination against smallpox. Pediatrics 1961, 27(2):219-226.
68. Griffith A.H., Kinsley B.J., Anderson D.J. A comparison between multiple puncture and intradermal methods of BCG vaccination. Tubercle 1963, 44(3):372-377.
69. de La Rocque F., Cohen R., Vie Le Sage F., Bocquet A., Boucherat M., Levy Bruhl D. Enquête sur les pratiques actuelles et futures du vaccin contre la tuberculose auprès des pédiatres et généralistes en France. Arch. de Pédiatrie 2005, 12(11):1665-1669.
70. Laurent A., Mistretta F., Bottigioli D., Dahel K., Goujon C., Nicolas J.F., et al. Echographic measurement of skin thickness in adults by high frequency ultrasound to assess the appropriate microneedle length for intradermal delivery of vaccines. Vaccine 2007, 25(34):6423-6430.
71. Arnou R., Icardi G., De Decker M., Ambrozaitis A., Kazek M-P., Weber F., et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 2009, 27(52):7304-7312.
72. Gupta J., Park S.S., Bondy B., Felner E.I., Prausnitz M.R. Infusion pressure and pain during microneedle injection into skin of human subjects. Biomaterials 2011, 32(28):6823-6831.
73. Seidenari S., Pagnoni A., di Nardo A.D., Giannetti A. Echographic evaluation with image analysis of normal skin: variations according to age and sex. Skin Pharmacol 1994, 7(4):201-209.
74. Alarcon J.B., Hartley A.W., Harvey N.G., Mikszta J.A. Preclinical evaluation of microneedle technology for intradermal delivery of influenza vaccines. Clin Vaccine Immunol 2007, 14(April (4)):375-381.
75. Mikszta J.A., Dekker J.P., Harvey N.G., Dean C.H., Brittingham J.M., Huang J., et al. Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine. Infect Immun 2006, 74(12):6806-6810.
76. Paccalin M., Weinberger B., Nicolas J.F., Van Damme P., Mégard Y. The intradermal vaccination route-an attractive opportunity for influenza vaccination in the elderly. Eur Geriatric Med 2010, 1(2):82-87.
77. Van Damme P., Arnou R., Kafeja F., Fiquet A., Richard P., Thomas S., et al. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC Infect Dis 2010, 10(1):134.
78. Laurent P.E., Bourhy H., Fantino M., Alchas P., Mikszta J.A. Safety and efficacy of novel dermal and epidermal microneedle delivery systems for rabies vaccination in healthy adults. Vaccine 2010, 28(36):5850-5856.
79. Van Damme P., Oosterhuis-Kafeja F., Van der Wielen M., Almagor Y., Sharon O., Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 2009, 27(3):454-459.
80. FDA. Available from: ; 2011 [cited 18th October 2011]. http://www.accessdata.fda.gov/SCRIPTs/cdrh/devicesatfda/index.cfm%3Fdb=pmn%26id=K092746.
81. Duggan S.T. Intanza 15μg intradermal seasonal influenza vaccine in older adults (aged 60 years): profile report. Bio Drugs 2010, 24:407-409.
82. Kim Y.-C., Quan F.-S., Yoo D.G., Compans R.W., Kang S.M., Prausnitz M.R. Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J Infect Dis 2010, 201(2):190-198.
83. Mikszta J.A., Alarcon J.B., Brittingham J.M., Sutter D.E., Pettis R.J., Harvey N.G. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat Med 2002, 8(4):415-419.
84. McAllister D.V., Wang P.M., Davis S.P., Park J-H., Canatella P.J., Allen M.G., et al. Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: Fabrication methods and transport studies. Proc Natl Acad Sci U S A 2003, 100(November (24)):13755-13760.
85. Kaushik S., Hord A.H., Denson D.D., McAllister D.V., Smitra S., Allen M.G., et al. Lack of pain associated with microfabricated microneedles. Anest Analg 2000, 92:502-504.
86. Gill H., Prausnitz M. Coating formulations for microneedles. Pharm Res 2007, 24(7):1369-1380.
87. Quan F-S., Kim Y-C., Compans R.W., Prausnitz M.R., Kang S-M. Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles. J Control Release 2010, 147(3):326-332.
88. Kim Y.-C., Quan F.-S., Compans R.W., Kang S.-M., Prausnitz M.R. Formulation of microneedles coated with influenza virus-like particle vaccine. AAPS PharmSciTech 2010, 11(3):1193-1201.
89. Wang P.M., Cornwell M., Hill J., Prausnitz M.R. Precise microinjection into skin using hollow microneedles. J Invest Dermatol 2006, 126(5):1080-1087.
90. Daugimont L., Baron N., Vandermeulen G., Pavselj N., Miklavcic D., Jullien M-C., et al. Hollow microneedle arrays for intradermal drug delivery and dna electroporation. J Membr Biol 2010, 236(1):117-125.
91. ® microprojection array patch technology: a new and efficient approach for intracutaneous immunization. Pharm Res 2002, 19(1):63-70.
92. Cormier M., Johnson B., Ameri M., Nyam K., Libiran L., Zhang D.D., et al. Transdermal delivery of desmopressin using a coated microneedle array patch system. J Control Release 2004, 97(3):503-511.
93. Kendall M., Rishworth S., Carter F., Mitchell T. Effects of relative humidity and ambient temperature on the ballistic delivery of micro-particles to excised porcine skin. J Investig Dermatol 2004, 122(3):739-746.
94. Hiraishi Y., Nandakumar S., Choi S-O., Lee J.W., Kim Y-C., Posey J.E., et al. Bacillus Calmette-Guérin vaccination using a microneedle patch. Vaccine 2011, 29(14):2626-2636.
95. Prausnitz M.R. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev 2004, 56(5):581-587.
96. Park J-H., Allen M., Prausnitz M. Polymer microneedles for controlled-release drug delivery. Pharm Res 2006, 23(5):1008-1019.
97. Miyano T., Tobinaga Y., Kanno T., Matsuzaki Y., Takeda H., Wakui M., et al. Sugar micro needles as transdermic drug delivery system. Biomed Microdevices 2005, 7(3):185-188.
98. Kolli C., Banga A. Characterization of solid maltose microneedles and their use for transdermal delivery. Pharm Res 2008, 25(1):104-113.
99. Lee K., Lee C.Y., Jung H. Dissolving microneedles for transdermal drug administration prepared by stepwise controlled drawing of maltose. Biomaterials 2011, 32(11):3134-3140.
100. Ito Y., Kashiwara S., Fukushima K., Takada K. Two-layered dissolving microneedles for percutaneous delivery of sumatriptan in rats. Drug Dev Ind Pharm 2011, 1-7.
101. Martanto W., Davis S., Holiday N., Wang J., Gill H., Prausnitz M. Transdermal delivery of insulin using microneedles in vivo. Pharm Res 2004, 21(6):947-952.
102. Gill H.S., Denson D.D., Burris B.A., Prausnitz M.R. Effect of microneedle design on pain in human volunteers. Clin J Pain 2008, 24(7):585-594.
103. Davis S.P., Martanto W., Allen M.G., Prausnitz M.R. Hollow metal microneedles for insulin delivery to diabetic rats. IEEE Trans Biomed Eng 2005, 52(5):909-915.
104. Widera G., Johnson J., Kim L., Libiran L., Nyam K., Daddona P.E., et al. Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system. Vaccine 2006, 24(10):1653-1664.
105. Bal S.M., Slütter B., Jiskoot W., Bouwstra J.A. Small is beautiful: N-trimethyl chitosan-ovalbumin conjugates for microneedle-based transcutaneous immunisation. Vaccine 2011, 29(23):4025-4032.
106. Pearton M., Kang S-M., Song J-M., Kim Y-C., Quan F-S., Anstey A., et al. Influenza virus-like particles coated onto microneedles can elicit stimulatory effects on Langerhans cells in human skin. Vaccine 2010, 28(37):6104-6113.
107. McAllister D.V., Allen M.G., Prausnitz M.R. Microfabricated microneedles for gene and drug delivery. Annu. Rev. Biomed. Eng. 2000, 2(1):289-313.
108. Park J-H., Allen M.G., Prausnitz M.R. Biodegradable polymer microneedles: fabrication, mechanics and transdermal drug delivery. J Control Release 2005, 104(1):51-66.
109. Zahn J.D., Talbot N.H., Liepmann D., Pisano A.P. Microfabricated polysilicon microneedles for minimally invasive biomedical devices. Biomed. Microdevices 2000, 2(4):295-303.
110. Zahn J.D., deshmukh A., Pisano A.P., Liepmann D. Continuous on-chip micropumping for microneedle enhanced drug delivery. Biomed. Microdevices 2004, 6(3):183-190.
111. Sivamani R.K., Stoeber B., Wu G.C., Zhai H., Liepmann D., Maibach H. Clinical microneedle injection of methyl nicotinate: stratum corneum penetration. Skin Res. Technol. 2005, 11(2):152-156.
112. Sivamani R.K., Stoeber B., Liepmann D., Maibach H.I. Microneedle penetration and injection past the stratum corneum in humans. J. Dermatol. Treat. 2009, 20(3):156-159.
113. Sivamani R.K., Liepmann D., Maibach H.I., Microneedles transdermal applications. Expert Opin Drug Delivery 2007, 4(1):19-25.
114. Kim Y-C., Prausnitz M. Enabling skin vaccination using new delivery technologies. Drug Delivery Translational Res 2011, 1(1):7-12.
115. Burton S., Ng C-Y., Simmers R., Moeckly C., Brandwein D., Gilbert T., et al. rapid intradermal delivery of liquid formulations using a hollow microstructured array. Pharm Res 2011, 28(1):31-40.
116. Gupta J., Gill H.S., Andrews S.N., Prausnitz M.R. Kinetics of skin resealing after insertion of microneedles in human subjects. J Controlled Release 2011, 154(2):148-155.
117. Kalluri H., Banga A., Formation Closure of microchannels in skin following microporation. Pharm Res 2011, 28(1):82-94.
118. Chu L.Y., Choi S-O., Prausnitz M.R. Fabrication of dissolving polymer microneedles for controlled drug encapsulation and delivery: bubble and pedestal microneedle designs. J Pharm Sci 2010, 99(10):4228-4238.
119. Raphael A.P., Prow T.W., Crichton M.L., Chen X., Fernando G.J.P., Kendall M.A.F. Targeted needle-free vaccinations in skin using multilayered, densely-packed dissolving microprojection arrays. Small 2010, 6(16):1785-1793.
120. Lee J.W., Choi S-O., Felner E.I., Prausnitz M.R. Dissolving microneedle patch for transdermal delivery of human growth hormone. Small 2011, 7(4):531-539.
121. Migalska K., Morrow D., Garland M., Thakur R., Woolfson A., Donnelly R. Laser-engineered dissolving microneedle arrays for transdermal macromolecular drug delivery. Pharm Res 2011, 1-12.
122. Bal S.M., Ding Z., Kersten G., Jiskoot W., Bouwstra J. Microneedle-based transcutaneous immunisation in mice with n-trimethyl chitosan adjuvanted diphtheria toxoid formulations. Pharm Res 2010, 27(9):1837-1847.
123. Ding Z., Van Riet E., Romeijn S., Kersten G., Jiskoot W., Bouwstra J. Immune modulation by adjuvants combined with diphtheria toxoid administered topically in BALB/c mice after microneedle array pretreatment. Pharm Res 2009, 26(7):1635-1643.
124. Ding Z., Verbaan F.J., Bivas-Benita M., Bungener L., Huckriede A., van den Berg D.J., et al. Microneedle arrays for the transcutaneous immunization of diphtheria and influenza in BALB/c mice. J Controlled Release 2009, 136(1):71-78.
125. Bal S.M., Caussin J., Pavel S., Bouwstra J.A. In vivo assessment of safety of microneedle arrays in human skin. Eur J Pharm Sci 2008, 35(3):193-202.
126. Ding Z., Bal S., Romeijn S., Kersten G., Jiskoot W., Bouwstra J. Transcutaneous immunization studies in mice using diphtheria toxoid-loaded vesicle formulations and a microneedle array. Pharm Res 2011, 28(1):145-158.
127. Gill H.S., Soderholm J., Prausnitz M.R., Sallberg M. Cutaneous vaccination using microneedles coated with hepatitis C DNA vaccine. Gene Ther 2010, 17(6):811-814.
128. Harvey A., Kaestner S., Sutter D., Harvey N., Mikszta J., Pettis R. Microneedle-based intradermal delivery enables rapid lymphatic uptake and distribution of protein drugs. Pharm Res 2011, 28(1):107-116.
129. Kim Y-C., Quan F-S., Yoo D-G., Compans R.W., Kang S-M., Prausnitz M.R. Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine 2009, 27(49):6932-6938.
130. Quan F-S., Kim Y-C., Vunnava A., Yoo D-G., Song J-M., Prausnitz M.R., et al. Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J Virol 2010, 84(August (15)):7760-7769.
131. Song J-M., Kim Y-C., Lipatov A.S., Pearton M., Davis C.T., Yoo D-G., et al. Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting b- and T-cell responses in mice. Clin Vaccine Immunol 2010, 17(September (9)):1381-1389.
132. van den Berg J.H., Nuijen B., Beijnen J.H., Vincent A., van Tinteren H., Kluge, et al. Optimization of intradermal vaccination by DNA tattooing in human skin. Hum Gene Ther 2009, 20(3):181-189.
133. Ciernik I.F., Krayenbühl B.H., Carbone D.P. Puncture-mediated gene transfer to the skin. Hum Gene Ther 1996, 7(8):893-899.
134. Bins A.D., Jorritsma A., Wolkers M.C., Hung C-F., Wu T.C., Schumacher T.N.M., et al. A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med 2005, 11(8):899-904.
135. Pokorná D., Poláková I., Kindlová M., Dusková M., Ludvíková V., Gabriel P., et al. Vaccination with human papillomavirus type 16-derived peptides using a tattoo device. Vaccine 2009, 27(27):3519-3529.
136. Pokorna D., Rubio I., Muller M. DNA-vaccination via tattooing induces stronger humoral and cellular immune responses than intramuscular delivery supported by molecular adjuvants. Genet Vaccines Ther 2008, 6(1):4.
137. Quaak S.G.L., den Berg JHv, Oosterhuis K., Beijnen J.H., Haanen J.B.A.G., Nuijen B. DNA tattoo vaccination: effect on plasmid purity and transfection efficiency of different topoisoforms. J Control Release 2009, 139(2):153-159.
138. Baxter J., Mitragotri S. Needle-free liquid jet injections: mechanisms and applications. Expert Rev Med Devices 2006, 3(5):565-574.
139. Giudice E.L., Campbell J.D. Needle-free vaccine delivery. Adv Drug Deliv Rev 2006, 58(1):68-89.
140. Baxter J., Mitragotri S. Jet-induced skin puncture and its impact on needle-free jet injections: experimental studies and a predictive model. J Control Release 2005, 106(3):361-373.
141. Haar H-P. Transdermales Injektionssystem EP application 0853952A1; July 1998.
142. Lell P. Needleless injection device with pyrotechnical drive. WO application 01/97880A2; December 2001.
143. Chase C.C.L., Daniels C.S., Garcia R. Needle-free injection technology in swine: progress toward vaccine efficacy and pork quality. J Swine Health Prod 2008, 16(5):254-261.
144. Grosenbaugh D., Leard T., Pardo M. Comparison of the safety and efficacy of a recombinant feline leukemia virus (FeLV) vaccine delivered transdermally and an inactivated FeLV vaccine delivered subcutaneously. Vet Ther 2004, 5:258-262.
145. Schramm-Baxter J., Mitragotri S. Needle-free jet injections: dependence of jet penetration and dispersion in the skin on jet power. J Control Release 2004, 97(3):527-535.
146. Jackson L.A., Austin G., Chen R.T., Stout R., DeStefano F., Gorse G.J., et al. Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. Vaccine 2001, 19(32):4703-4709.
147. Cui Z., Baizer L., Mumper R.J. Intradermal immunization with novel plasmid DNA-coated nanoparticles via a needle-free injection device. J Biotechnol 2003, 102(2):105-115.
148. Williams J., Fox-Leyva L., Christensen C., Fisher D., Schlicting E., Snowball M., et al. Hepatitis A vaccine administration: comparison between jet-injector and needle injection. Vaccine 2000, 18(18):1939-1943.
149. Lemon S.M., Scott R.M., Bancroft W.H. Subcutaneous administration of inactivated hepatitis B vaccine by automatic jet injection. J. Med. Virol. 1983, 12(2):129-136.
150. Babiuk S., Baca-Estrada M., Babiuk L.A., Ewen C., Foldvari M. Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery. J Control Release 2000, 66(2-3):199-214.
151. Aguiar J.C., Hedstrom R.C., Rogers W.O., Charoenvit Y., Sacci J.B., Lanar D.E., et al. Enhancement of the immune response in rabbits to a malaria DNA vaccine by immunization with a needle-free jet device. Vaccine 2001, 20(1-2):275-280.
152. Michinaka Y., Mitragotri S. Delivery of polymeric particles into skin using needle-free liquid jet injectors. J Control Release 2011, 153(3):249-254.
153. Sarno M.J., Blase E., Galindo N., Ramirez R., Schirmer C.L., Trujillo-Juarez D.F. Clinical immunogenicity of measles, mumps and rubella vaccine delivered by the Injex jet injector: comparison with standard syringe injection. Pediatr Infect Dis J 2000, 19(9):839-842.
154. Benedek K., Walker E., Doshier L.A., Stout R. Studies on the use of needle-free injection device on proteins. J Chromatogr A 2005, 1079(1-2):397-407.
155. Gorres J.P., Lager K.M., Kong W.-P., Royals M., Todd J.-P., Vincent A.L., et al. DNA vaccination elicits protective immune responses against pandemic and classic swine influenza viruses in pigs. Clin Vaccine Immunol 2011, 18(11):1987-1995.
156. FDA.Available from: [cited 20th October 2011]. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm%3FID=36147.
157. Klein T.M., Wolf E.D., Wu R., Sanford J.C. High-velocity microprojectiles for delivering nucleic acids into living cells. Nature 1987, 327(6117):70-73.
158. Fuller D.H., Loudon P., Schmaljohn C. Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods 2006, 40(1):86-97.
159. Bellhouse BJ, Sarphie D.F., Greenford JC. Needleless syringe using supersonic gas flow for particle delivery; 1999.
160. Roberts L.K., Barr L.J., Fuller D.H., McMahon C.W., Leese P.T., Jones S. Clinical safety and efficacy of a powdered Hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device. Vaccine 2005, 23(40):4867-4878.
161. Kendall M.A.F., Quinlan N.J., Thorpe S.J., Ainsworth R.W., Bellhouse B.J. Measurements of the gas and particle flow within a converging-diverging nozzle for high speed powdered vaccine and drug delivery. Exp Fluids 2004, 37(1):128-136.
162. Burkoth T.L., Bellhouse B.J., Hewson G., Longridge D.J., Muddle A.G., Sarphie D.F. Transdermal and transmucosal powdered drug delivery. Crit Rev Ther Drug Carr Syst 1999, 16(4):331-384.
163. Chen D., Endres R.L., Erickson C.A., Weis K.F., McGregor M.W., Kawaoka Y., et al. Epidermal immunization by a needle-free powder delivery technology: immunogenicity of influenza vaccine and protection in mice. Nat Med 2000, 6(10):1187-1190.
164. Roy M.J., Wu M.S., Barr L.J., Fuller J.T., Tussey L.G., Speller S., et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2000, 19(7-8):764-778.
165. Quinlan N.J., Kendall M.A.F., Bellhouse B.J., Ainsworth R.W. Investigations of gas and particle dynamics in first generation needle-free drug delivery devices. Shock Waves 2001, 10(6):395-404.
166. Liu Y., Kendall M. Numerical simulation of heat transfer from a transonic jet impinging on skin for needle-free powdered drug and vaccine delivery. Proceedings of the Institution of Mechanical Engineers, Part C: J Mech Eng Sci 2004, 218(11):1373-1383.
167. Kendall M.A.F. The delivery of particulate vaccines and drugs to human skin with a practical, hand-held shock tube-based system. Shock Waves 2002, 12(1):23-30.
168. Liu Y., Truong N., Kendall M., Bellhouse B. Characteristics of a micro-biolistic system for murine immunological studies. Biomed Microdevices 2007, 9(4):465-474.
169. Kendall M.A.F. Needle-free vaccine injection. Drug DeliveryBerlin Heidelberg 2010, Springer, Berlin Heidelberg, pp. 193-219.
170. Liu Y., Mark A.F.K. Optimization of a jet-propelled particle injection system for the uniform transdermal delivery of drug/vaccine. Biotechnol Bioeng 2007, 97(5):1300-1308.
171. Liu Y., Kendall M. Numerical analysis of gas and micro-particle interactions in a hand-held shock-tube device. Biomed Microdevices 2006, 8(4):341-351.
172. Liu Y. Utilization of the venturi effect to introduce micro-particles for epidermal vaccination. Med Eng Phys 2007, 29(3):390-397.
173. Liu Y., Costigan G., Bellhouse B.J. Performance studies of a conical nozzle designed for the macromolecular skin delivery. J Drug Target 2008, 16(3):206-212.
174. Liu Y., Costigan G., Bellhouse B.J. Swirling effects on the performance of the micro-particle acceleration and penetration: parametric studies. Powder Technol 2008, 183(2):189-195.
175. Chen D., Weis K.F., Chu Q., Erickson C., Endres R., Lively C.R., et al. Epidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses. J Virol 2001, 75(December (23)):11630-11640.
176. Dean H.J. Epidermal delivery of protein and DNA vaccines. Expert Opin Drug Deliv 2005, 2(2):227-236.
177. Lesinski G.B., Smithson S.L., Srivastava N., Chen D., Widera G., Westerink M.A.J. A DNA vaccine encoding a peptide mimic of Streptococcus pneumoniae serotype 4 capsular polysaccharide induces specific anti-carbohydrate antibodies in Balb/c mice. Vaccine 2001, 19(13-14):1717-1726.
178. Raju P.A., McSloy N., Truong N.K., Kendall M.A.F. Assessment of epidermal cell viability by near infrared multi-photon microscopy following ballistic delivery of gold micro-particles. Vaccine 2006, 24(21):4644-4647.
179. Tacket C.O., Roy M.J., Widera G., Swain W.F., Broome S., Edelman R. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine 1999, 17(22):2826-2829.
180. Lebre F., Borchard G., de Lima M., Borges O., Progress Towards a needle-free hepatitis B vaccine. Pharm Res 2010, 1-27.
181. Eisenbraun M.D., Fuller D.H., Haynes J.R. Examination of parameters affecting the elicitation of humoral immune responses by particle bombardment-mediated genetic immunization. DNA Cell Biol 1993, 12(9):791-797.
182. Rottinghaus S.T., Poland G.A., Jacobson R.M., Barr L.J., Roy M.J., Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination. Vaccine 2003, 21(31):4604-4608.
183. Drape R.J., Macklin M.D., Barr L.J., Jones S., Haynes J.R., Dean H.J. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 2006, 24(21):4475-4481.
184. Schiffter H, Condliffe J, Vonhoff S. Spray-freeze-drying of nanosuspensions: the manufacture of insulin particles for needle-free ballistic powder delivery. J R Soc Interface 2010; June 2.
185. Maa Y-F., Ameri M., Shu C., Payne L.G., Chen D. Influenza vaccine powder formulation development: spray-freeze-drying and stability evaluation. J Pharm Sci 2004, 93(7):1912-1923.
186. Maa Y-F., Ameri M., Shu C., Zuleger C.L., Che J., Osorio J.E., et al. Hepatitis-B surface antigen (HBsAg) powder formulation: process and stability assessment. Curr Drug Deliv 2007, 4:57-67.
187. Maa Y-F., Zhao L., Payne L.G., Chen D. Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application. J Pharm Sci 2002, 92(2):319-332.
188. Sonner C., Maa Y-F., Lee G. Spray-freeze-drying for protein powder preparation: particle characterization and a case study with trypsinogen stability. J Pharm Sci 2002, 91(10):2122-2139.
189. Rochelle C., Lee G. Dextran or hydroxyethyl starch in spray-freeze-dried trehalose/mannitol microparticles intended as ballistic particulate carriers for proteins. J Pharm Sci 2007, 96(9):2296-2309.
190. Hardy M.P., Kendall M.A.F. Mucosal deformation from an impinging transonic gas jet and the ballistic impact of microparticles. Phys Med Biol 2005, 50(19):4567.
191. Chen D., Erickson C.A., Endres R.L., Periwal S.B., Chu Q., Shu C., et al. Adjuvantation of epidermal powder immunization. Vaccine 2001, 19(20-22):2908-2917.
192. Truong N., Liu Y., Kendall M. Gas and particle dynamics of a contoured shock tube for pre-clinical microparticle drug delivery. Shock Waves 2006, 15(3):149-164.
193. Chen D., Zuleger C., Chu Q., Maa Y.F., Osorio J., Payne L.G. Epidermal powder immunization with a recombinant HIV gp120 targets langerhans cells and induces enhanced immune responses. AIDS Res Hum Retroviruses 2002, 18(10):715-722.
194. Osorio J.E., Zuleger C.L., Burger M., Chu Q., Payne L.G., Chen D. Immune responses to hepatitis B surface antigen following epidermal powder immunization. Immunol Cell Biol 2003, 81(1):52-58.
195. Abdul-Fattah A., Truong-Le V., Yee L., Pan E., Ao Y., Kalonia D., et al. Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on stability ii: stability of a vaccine. Pharm Res 2007, 24(4):715-727.
196. Amorij J.P., Huckriede A., Wilschut J., Frijlink H., Hinrichs W. Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm Res 2008, 25(6):1256-1273.
197. Ito Y., Hagiwara E., Saeki A., Sugioka N., Takada K. Feasibility of microneedles for percutaneous absorption of insulin. Eur J Pharm Sci 2006, 29(1):82-88.
198. Oh J-H., Park H-H., Do K-Y., Han M., Hyun D-H., Kim C-G., et al. Influence of the delivery systems using a microneedle array on the permeation of a hydrophilic molecule, calcein. Eur J Pharm Biopharm 2008, 69(3):1040-1045.
199. Lee J.W., Park J-H., Prausnitz M.R. Dissolving microneedles for transdermal drug delivery. Biomaterials 2008, 29(13):2113-2124.
200. Park J-H., Choi S-O., Seo S., Choy Y.B., Prausnitz M.R. A microneedle roller for transdermal drug delivery. Eur J Pharm Biopharm 2010, 76(2):282-289.
201. Ito Y., Yoshimitsu J-I., Shiroyama K., Sugioka N., Takada K. Self-dissolving microneedles for the percutaneous absorption of EPO in mice. J Drug Target 2006, 14(5):255-261.
202. Wu Y., Qiu Y., Zhang S., Qin G., Gao Y. Microneedle-based drug delivery: studies on delivery parameters and biocompatibility. Biomed Microdevices 2008, 10:601-610.
203. Baek C., Han M., Min J., Prausnitz M.R., Park J.-H., Park J. Local transdermal delivery of phenylephrine to the anal sphincter muscle using microneedles. J Control Release 2011, 154(2):138-147.
204. Ito Y., Shiroyama K., Yoshimitsu J., Ohashi Y., Sugioka N., Takada K. Pharmacokinetic and pharmacodynamic studies following percutaneous absorption of erythropoietin micropiles to rats. J Control Release 2007, 121(3):176-180.
205. McAllister D.V., Henry S., Allen M.G., Prausnitz M.R. Microfabricated microneedles: a novel approach to transdermal drug delivery. Proc Int Symp Controlled Release Bioact Mater 1998, 25:30-31.
206. Andrianov A.K., DeCollibus D.P., Gillis H.A., Kha H.H., Marin A., Prausnitz M.R., et al. Poly[di(carboxylatophenoxy)phosphazene] is a potent adjuvant for intradermal immunization. Proc Natl Acad Sci 2009, 106(November (45)):18936-18941.
207. Cosman F., Lane N.E., Bolognese M.A., Zanchetta J.R., Garcia-Hernandez P.A., Sees K., et al. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2010, 95(January (1)):151-158.
208. Mikszta J.A., Sullivan V.J., Dean C., Waterston A.M., Alarcon J.B., Dekker J.P., et al. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. J Infect Dis 2005, 191(January (2)):278-288.
209. Ito Y., Murakami A., Maeda T., Sugioka N., Takada K. Evaluation of self-dissolving needles containing low molecular weight heparin (LMWH) in rats. Int J Pharm 2008, 349(1-2):124-129.
210. Davis S.P., Landis B.J., Adams Z.H., Allen M.G., Prausnitz M.R. Insertion of microneedles into skin: measurement and prediction of insertion force and needle fracture force. J Biomech 2004, 37(8):1155-1163.